Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
Year: 2020
Type: article
Source: European Journal of Cancer
Authors: Dario Pasalic, Gwendolyn J. McGinnis, C. David Fuller, Aaron J. Grossberg, Vivek Verma, Walker Mainwaring, Austin B. Miller, Timothy A. Lin, Amit Jethanandani, Andres F. Espinoza, Markus Diefenhardt, Prajnan Das, Vivek Subbiah, Ishwaria M. Subbiah, Reshma Jagsi, Adam S. Garden, Emmanouil Fokas, Claus Rödel, Charles R. Thomas, Bruce D. Minsky, Ethan B. Ludmir
Institutions: The University of Texas MD Anderson Cancer Center, Oregon Health & Science University, Allegheny Health Network, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Johns Hopkins University, University of Tennessee Health Science Center, Goethe University Frankfurt, Frankfurt Cancer Institute, University of Michigan, German Cancer Research Center, Deutsches Konsortium für Translationale Krebsforschung
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W3042531629